دورية أكاديمية
The prognostic implications and tumor-promoting functions of CHSY3 in gastric cancer.
| العنوان: | The prognostic implications and tumor-promoting functions of CHSY3 in gastric cancer. |
|---|---|
| المؤلفون: | Wang H; Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.; Department of Gastrointestinal Surgery, Department of General Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China., Zhang J; Department of Gastrointestinal Surgery, First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China., Wei Z; Department of Gastrointestinal Surgery, First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China., Chen S; Digestive Diseases Center, The Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen, Guangdong, China., Zheng J; Department of Gastrointestinal Surgery, Department of General Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China., Li Y; Department of Gastrointestinal Surgery, Department of General Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China. |
| المصدر: | Frontiers in immunology [Front Immunol] 2024 May 15; Vol. 15, pp. 1364979. Date of Electronic Publication: 2024 May 15 (Print Publication: 2024). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Research Foundation] |
| مواضيع طبية MeSH: | Cell Proliferation* , Stomach Neoplasms*/pathology , Stomach Neoplasms*/genetics , Stomach Neoplasms*/mortality , Stomach Neoplasms*/metabolism , Stomach Neoplasms*/immunology, Aged ; Female ; Humans ; Male ; Middle Aged ; Biomarkers, Tumor/metabolism ; Cell Line, Tumor ; Cell Movement ; Gene Expression Regulation, Neoplastic ; Prognosis ; Tumor-Associated Macrophages/immunology ; Tumor-Associated Macrophages/metabolism |
| مستخلص: | Chondroitin sulfate synthase 3 (CHSY3) is an important enzyme that regulates glycosylation, but its role in tumors has not been determined. Here, we showed that high CHSY3 expression promotes proliferation in gastric cancer (GC) cells and is associated with poor prognosis in GC patients. We analyzed the immunohistochemistry data of 150 gastric cancer patients to determine the clinicopathological and survival significance of CHSY3. Immunofluorescence was used to detect the colocalization of CHSY3 with infiltrating immune cells. Additionally, CHSY3 was predominantly found in tumor tissues and showed higher abundance compared to matched adjacent tissues. High CHSY3 expression was associated with more advanced tumor stage, higher recurrence risk and worse survival. Immunohistochemistry and bioinformatic analysis revealed that CHSY3 expression was significantly positively correlated with tumor-associated macrophage (TAM) infiltration. Moreover, after knocking down CHSY3, the proliferation of cells was decreased, and the migration ability was reduced, as shown by scratch, monoclonal and transwell assays. In conclusion, this study revealed that CHSY3 has a tumor-promoting effect on GC, suggesting a novel therapeutic strategy against this disease. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2024 Wang, Zhang, Wei, Chen, Zheng and Li.) |
| References: | J Transl Med. 2023 Jul 17;21(1):474. (PMID: 37461041) Int J Biol Macromol. 2023 Dec 31;253(Pt 1):126551. (PMID: 37659488) Int J Med Sci. 2021 Jan 1;18(1):207-215. (PMID: 33390789) Gastroenterology. 2023 Mar;164(3):392-406.e5. (PMID: 36402190) Cancer Cell. 2019 Jul 8;36(1):6-16. (PMID: 31287993) Sci Transl Med. 2015 Apr 8;7(282):282ra47. (PMID: 25855493) Lancet Oncol. 2003 Jun;4(6):351-8. (PMID: 12788407) J Hepatol. 2020 Jul;73(1):186-201. (PMID: 32240716) Signal Transduct Target Ther. 2021 Feb 23;6(1):75. (PMID: 33619259) J Biol Chem. 2003 Aug 8;278(32):30235-47. (PMID: 12761225) Nat Commun. 2023 Jan 13;14(1):201. (PMID: 36639369) Mol Cancer. 2023 Mar 21;22(1):58. (PMID: 36941614) Front Immunol. 2020 Dec 03;11:583084. (PMID: 33365025) Cancer Res. 2021 Mar 1;81(5):1201-1208. (PMID: 33203697) Int J Surg. 2024 Feb 01;110(2):1000-1007. (PMID: 38085808) Front Genet. 2022 Apr 27;13:876588. (PMID: 35571047) Cell Cycle. 2021 Sep;20(18):1861-1874. (PMID: 34412565) J Clin Invest. 2016 Nov 1;126(11):4157-4173. (PMID: 27721235) PLoS One. 2012;7(8):e43806. (PMID: 22952769) Annu Rev Pathol. 2022 Jan 24;17:295-321. (PMID: 34736341) Oncol Lett. 2018 Nov;16(5):6140-6146. (PMID: 30344756) Neuro Oncol. 2017 May 1;19(5):648-659. (PMID: 28453746) Lancet. 2020 Aug 29;396(10251):635-648. (PMID: 32861308) Nat Rev Clin Oncol. 2018 Jul;15(7):459-466. (PMID: 29666440) Nat Rev Cancer. 2015 Sep;15(9):540-55. (PMID: 26289314) Nat Rev Cancer. 2019 Mar;19(3):151-161. (PMID: 30723290) Front Immunol. 2023 Aug 24;14:1212476. (PMID: 37691932) Mol Cell Biol. 2020 Jan 16;40(3):. (PMID: 31767633) Biosci Rep. 2022 Jul 29;42(7):. (PMID: 35727208) Clin Cancer Res. 2019 Jul 1;25(13):3873-3886. (PMID: 30890553) Trends Plant Sci. 2018 Dec;23(12):1068-1080. (PMID: 30279071) Immunity. 2023 Jan 10;56(1):32-42. (PMID: 36630916) J Exp Clin Cancer Res. 2023 Sep 25;42(1):248. (PMID: 37749638) Cancer Lett. 2017 Sep 10;403:280-288. (PMID: 28652022) Oncogenesis. 2020 Feb 4;9(2):9. (PMID: 32019907) World J Gastroenterol. 2023 Feb 14;29(6):997-1010. (PMID: 36844144) CA Cancer J Clin. 2020 Mar;70(2):86-104. (PMID: 31944278) Cell Mol Immunol. 2020 Jan;17(1):27-35. (PMID: 31853000) Nat Rev Drug Discov. 2019 Mar;18(3):175-196. (PMID: 30622344) |
| فهرسة مساهمة: | Keywords: CHSY3; gastric cancer; prognosis; tumor immune microenvironment; tumor-associated macrophages |
| المشرفين على المادة: | 0 (Biomarkers, Tumor) EC 2.4.1.175 (CHSY3 protein, human) |
| تواريخ الأحداث: | Date Created: 20240530 Date Completed: 20240530 Latest Revision: 20240606 |
| رمز التحديث: | 20240606 |
| مُعرف محوري في PubMed: | PMC11133601 |
| DOI: | 10.3389/fimmu.2024.1364979 |
| PMID: | 38812506 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2024.1364979 |